Intermittent vs continuous androgen deprivation therapy for prostate cancer

JAMA Oncology

Volumn 1, Issue 9, 2015, Pages 1261-1269

  Magnan, Sindy ^a   Zarychanski, Ryan ^b,c   Pilote, Laurie ^a   Bernier, Laurence ^a   Shemilt, Michèle ^d   Vigneault, Eric ^a,d   Fradet, Vincent ^a,d   Turgeon, Alexis F ^a,d  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Cancercare Manitoba ^*  (Canada)

^d University Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; HUMAN; MALE; META ANALYSIS; MORTALITY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84983488635     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2895     Document Type: Article

References (47)

1. Ferlay J, Soerjomataram I, ErvikM, et al; International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, 2013, Cancer Incidence and MortalityWorldwide: IARC CancerBase No. 11. http: //globocan.iarc.fr. Accessed February 27, 2014.
2. Mohler JL, Kantoff PW, Armstrong AJ, et al; National comprehensive cancer network. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013;11(12):1471-1479.
3. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93(7):975-979.
4. Herr HW, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer. 1993;71(3)(suppl):1143-1150.
5. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163(6):1743-1746.
6. Nishiyama T, Kanazawa S,Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004;11(9):735-741.
7. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32 (49):5501-5511.
8. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993;71(9):2782-2790.
9. Sato N, GleaveME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996;58(2):139-146.
10. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev. 2007;(4):CD005009.
11. Heidenreich A, Bastian PJ, Bellmunt J, et al; European Association of Urology. EAU guidelines on prostate cancer, part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467-479.
12. Horwich A, Parker C, de Reijke T, Kataja V; ESMO GuidelinesWorking Group. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi106-vi114.
13. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367 (10):895-903.
14. HussainM, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013; 368(14):1314-1325.
15. Calais da Silva F, Calais da Silva FM, Gonçalves F, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group [published online April 4, 2013]. Eur Urol. 2014;66(2):232-239.
16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. http://handbook.cochrane .org/. Accessed July 21, 2015.
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
18. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc. 2006;94(1):41-47.
19. McKibbon KA,Wilczynski NL, Haynes RB; Hedges Team. Retrieving randomized controlled trials from MedLine: a comparison of 38 published search filters. Health Info Libr J. 2009;26(3):187-202.
20. Hackshaw A. A Concise Guide to Clinical Trials. Oxford, England: Wiley-Blackwell; 2009:205-207.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834.
22. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in ameta-analysis. Stat Med. 2002; 21(11):1539-1558.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560.
25. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176(8): 1091-1096.
26. Atkins D, Eccles M, Flottorp S, et al; GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.
27. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55 (6):1269-1277.
28. Calais Da Silva Junior FM, Bono A, Whelan P, et al. Phase III study of intermittent MAB vs continuous MAB. Eur Urol Suppl. 2011;10(2):253.
29. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1(3):163-171.
30. Hering F, Rodrigues PRT, LipayMA, Nesrallah L, Srougi M. Metastatic adenocarcinoma of the prostate: comparison between continuous and intermittent hormonal treatment [in Portuguese]. Braz J Urol. 2000;26(3):276-282.
31. Irani J, Celhay O, Hubert J, et al; Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol. 2008;54(2):382-391.
32. Koga H, Naito S, Ito K, et al. Quality of life in locally advanced prostate cancer patients who underwent hormonal treatment combined with radiotherapy [in Japanese]. Nishi Nihon Hinyokika [West Japan J Urol]. 2004;66(4):255-262.
33. Langenhuijsen JF, Schasfoort EMC, Heathcote P, et al. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data. Eur Urol Suppl. 2008;7 (3):205.
34. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LALM, Witjes JA, Mulders PFA. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer [published online May 10, 2011]. Urol Oncol. 2013;31(5):549-556.
35. Miller K, Steiner U, Lingnau A, et al. Intermittent vs continuous androgen suppression in advanced prostate cancer: a randomised prospective study. J Urol. 2007;177(4):573.
36. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A,Wolff JM; TAP22 Investigators Group. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int. 2012;110(9):1262-1269.
37. Organ M,Wood L, Wilke D, et al. Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Am J Clin Oncol. 2013;36(6):601-605.
38. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects [published online July 27, 2012]. Eur Urol. 2013;63(1):111-120.
39. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TLJ; FinnProstate Group. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol. 2012;187(6): 2074-2081.
40. Schasfoort EMC, Heathcote P, Lock MTWT, et al. Intermittent androgen suppressionwith buserelin and nilutamide for the treatment of prostate cancer patients. Eur Urol Suppl. 2003;2(1):187.
41. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int. 2007;99(suppl 1):19-22.
42. Tunn UW, Canepa G, Hillger H, FuchsW. Intermittent androgen deprivation in patients with PSA-Relapse after radical prostatectomy: final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507. J Urol. 2007;177(4):201.
43. Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2012;15(3):296-302.
44. Verhagen PC,Wildhagen MF, Verkerk AM, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial [published online November 21, 1013].World J Urol. 2014;32(5):1287-1294.
45. Yamanaka H, Ito K, Naito S, et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate. 2005;63(1):56-64.
46. Botrel TE, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9.
47. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013;31 (16):2029-2036.